Published in Oncotarget on July 30, 2014
Methylation of MGMT and ADAMTS14 in normal colon MUCOSA: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans. Oncotarget (2015) 0.83
New insights into the genetics of glioblastoma multiforme by familial exome sequencing. Oncotarget (2015) 0.77
ILKAP, ILK and PINCH1 control cell survival of p53-wildtype glioblastoma cells after irradiation. Oncotarget (2015) 0.76
Mammalian APE1 controls miRNA processing and its interactome is linked to cancer RNA metabolism. Nat Commun (2017) 0.75
APE1 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis. Oncotarget (2017) 0.75
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A (2002) 30.32
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics (2010) 26.76
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Playing the end game: DNA double-strand break repair pathway choice. Mol Cell (2012) 5.42
DNA interstrand crosslink repair and cancer. Nat Rev Cancer (2011) 4.29
Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol (2006) 3.76
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer (2004) 3.27
Human cancers express a mutator phenotype. Proc Natl Acad Sci U S A (2006) 3.11
The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal (2009) 2.43
Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science (2013) 2.38
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.08
Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg (2006) 1.93
Mammalian base excision repair: the forgotten archangel. Nucleic Acids Res (2013) 1.79
Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res (1999) 1.66
O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol (2006) 1.66
Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat Rev (2010) 1.50
Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res (2002) 1.46
Overview of base excision repair biochemistry. Curr Mol Pharmacol (2012) 1.36
Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res (2001) 1.36
NBS1 and its functional role in the DNA damage response. DNA Repair (Amst) (2004) 1.30
Nucleotide excision repair: new tricks with old bricks. Trends Genet (2012) 1.28
Brain tumor-polyposis syndrome: two genetic diseases? J Clin Oncol (1997) 1.27
Treatment of high-grade glioma in children and adolescents. Neuro Oncol (2011) 1.27
Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res (2006) 1.25
Mammalian mismatch repair: error-free or error-prone? Trends Biochem Sci (2012) 1.21
Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther (2012) 1.15
APE1/Ref-1 regulates PTEN expression mediated by Egr-1. Free Radic Res (2008) 1.13
Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int J Cancer (2012) 1.04
A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. Breast Cancer Res Treat (2009) 1.03
Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation. Clin Cancer Res (2006) 1.01
PTEN in DNA damage repair. Cancer Lett (2012) 0.98
FOXG1-Related Disorders: From Clinical Description to Molecular Genetics. Mol Syndromol (2011) 0.94
DACH1: its role as a classifier of long term good prognosis in luminal breast cancer. PLoS One (2014) 0.89
Transcription factors FOXG1 and Groucho/TLE promote glioblastoma growth. Nat Commun (2013) 0.88
Identification of glioma-specific RFX4-E and -F isoforms and humoral immune response in patients. Cancer Sci (2005) 0.86
Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology. Neuro Oncol (2010) 0.86
DNA repair in cancer: emerging targets for personalized therapy. Cancer Manag Res (2014) 0.86
Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer. Breast Cancer Res Treat (2014) 0.84
Linking PTEN with genomic instability and DNA repair. Cell Cycle (2009) 0.83
Molecular basis of the brain tumor-polyposis (Turcot) syndrome. Pediatr Dev Pathol (2004) 0.79
Prognostic implications of the DNA damage response pathway in glioblastoma. Oncol Rep (2011) 0.77
Increased expression of phosphorylated NBS1, a key molecule of the DNA damage response machinery, is an adverse prognostic factor in patients with de novo myelodysplastic syndromes. Leuk Res (2013) 0.76
RECQL4 helicase has oncogenic potential in sporadic breast cancers. J Pathol (2016) 0.81
Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer. Oncotarget (2016) 0.79